CAR-T cell therapy Flashcards Preview

Hematology, oncology > CAR-T cell therapy > Flashcards

Flashcards in CAR-T cell therapy Deck (18)
Loading flashcards...
1
Q

Basic process

A

T-cells engineered/modified to recognize cancer cells –> grown and cultured –> lymphodeplete pt (prevent rejection) –> infuse into patients

2
Q

Medication used for lymphodepletion

A

Cytarabine, cytoxan

3
Q

most important SE’s to know about

A
  • cytokine release syndrome
  • neurotoxicity (can be delayed)
  • HLH/MAS
  • B-cell aplasia leading to hypogammaglobulinemia
  • infections (during lymphodepletion)
  • TLS
  • prolonged cytopenia
4
Q

Problem you don’t want to have if other providers are unaware of CAR-T

A

Patients get transfused high dose steroids and you kill engineered cells

5
Q

vector delivery

A

viral

6
Q

CAR-T products available

A

kymriah
yescarta
tecartus
one other

7
Q

management of hypogammaglobulinemia resulting from CAR-T

A

IF infection –> IVIG

8
Q

most common toxicity of cellular immunotherapy

A

CRS

9
Q

variables involved in CRS grading

A

fever
hypotension
hypoxia

10
Q

second line treatment of CRS

A

steroids

11
Q

first line treatment of CRS

A

tocilizumab

12
Q

second most common SE of CAR-T

A

neurotoxicity

13
Q

Neurotoxicity presentation

A

anything (seizure, HA, encephalopathy, delirium)

14
Q

Term for encephalopathy stemming from CAR-T

A

Immune effector cell-associated encephalopathy

15
Q

Outpatient CAR-T?

A

Depends on product

16
Q

Kymriah generic name

A

Tisagenlecleucel

17
Q

CAR T approved indications

A

1) relapsed or refractory B cell ALL
2) relapsed or refractory DLBCL
3) high grade B cell lymphoma
4) DLBCL arising from follicular lymphoma
5) High grade follicular lymphoma
6) Relapsed or refractory multiple myeloma
7) relapsed or refractory MCL

18
Q

Target of idecabtagene vicleucel

A

BCMA

Decks in Hematology, oncology Class (218):